Actively Recruiting
A Prospective Research Investigation of Ischemia Using MCG
Led by SB Technology, Inc. · Updated on 2025-10-21
150
Participants Needed
2
Research Sites
89 weeks
Total Duration
On this page
Sponsors
S
SB Technology, Inc.
Lead Sponsor
M
Mayo Clinic
Collaborating Sponsor
AI-Summary
What this Trial Is About
PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
CONDITIONS
Official Title
A Prospective Research Investigation of Ischemia Using MCG
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction
- Ability for participant to comply with study requirements
- Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities
- Written informed consent
You will not qualify if you...
- Present STEMI
- Pregnant or breastfeeding
- Having an active atrial fibrillation episode as seen on most current 12-lead ECG
- Active thoracic metal implant
- Poor access to follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
2
Mount Sinai Hospital
New York, New York, United States, 10029
Actively Recruiting
Research Team
M
Maggie LeDang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here